Categories
Update

Novo Nordisk A/S (NYSE: NVO)

One of the world leaders in the production of new diabetes drugs

Novo Nordisk A/S is a Danish multinational pharmaceutical company focused on diabetes care, medicines, and devices. Its main product is the drugĀ semaglutide, which is used to treat diabetes under the brand name Ozempic. It markets a similar formulation forĀ  weight loss under the brand name Wegovy.

Wealth Builder

Sorry!

Only current subscribers of the Internet Wealth Builder may view the details of this recommendation.






Interactive Performance Chart

NVO was first recommended here on October 15, 2023